Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin

NCT01695954 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01695954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01695954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
January 31, 2013
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hyperlipidemia